While the current gene therapy development efforts target life-threatening lung disease via CFTR replacement (gene addition) or mutation repair (gene editing), it is worth mentioning that Cl− secretion in airway epithelial cells is not limited to CFTR. The gene discussed is CFTR; the disease is lung disorder.